Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Liver International Pub Date : 2024-12-21 DOI:10.1111/liv.16204

Ana Virseda-Berdices, Rubén Martín-Escolano, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, Luis Ibañez-Samaniego, Elba Llop-Herrera, Antonio Olveira, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, María Ángeles Jiménez-Sousa, the ESCORIAL Study Group

{"title":"Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients","authors":"Ana Virseda-Berdices, Rubén Martín-Escolano, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, Luis Ibañez-Samaniego, Elba Llop-Herrera, Antonio Olveira, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, María Ángeles Jiménez-Sousa, the ESCORIAL Study Group","doi":"10.1111/liv.16204","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography–mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We found that increases of 2,3-butanediol (AMR = 1.15; <i>q</i>-value = 0.023) and taurocholic acid (AMR = 1.06; <i>q</i>-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These metabolites have a potential role as indicators of portal hypertension evolution.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.16204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aims

In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.

Methods

We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography–mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.

Results

We found that increases of 2,3-butanediol (AMR = 1.15; q-value = 0.023) and taurocholic acid (AMR = 1.06; q-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.

Conclusions

These metabolites have a potential role as indicators of portal hypertension evolution.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HCV肝硬化患者DAAs治疗后与HVPG变化相关的代谢组学变化

背景和目的：在直接作用抗病毒药物（DAAs）治疗中，经历肝静脉压梯度（HVPG）降低的患者显著减少了肝脏并发症并提高了生存率。本研究旨在评估晚期hcv相关性肝硬化患者从DAA治疗开始到DAA治疗有效后48周与HVPG变化相关的代谢组学变化。方法：我们对31例晚期丙型肝炎病毒（HCV）相关肝硬化患者进行了多中心纵向研究。我们使用气相色谱-质谱法和液相色谱-质谱法进行了非靶向代谢组学分析，并使用Luminex技术分析了炎症相关的生物标志物。采用广义线性混合效应模型（GLMM）进行统计分析，校正多重检验。结果：2,3-丁二醇增加(AMR = 1.15；q值= 0.023)和牛磺胆酸(AMR = 1.06；结论：这些代谢物具有作为门脉高压演变指标的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.